These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 8068416)

  • 1. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
    Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
    Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
    DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates.
    Reeves JP; Lo CY; Klinman DM; Epstein SL
    Hybridoma; 1995 Jun; 14(3):235-42. PubMed ID: 7590785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
    Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC
    Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
    J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development.
    Veljkovic V; Metlas R
    Vaccine; 1993; 11(3):291-2. PubMed ID: 8447156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
    Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mapping of HIV-1 gp160 epitopes required for interleukin-1 and tumor necrosis factor alpha production in glial cells.
    Koka P; He K; Camerini D; Tran T; Yashar SS; Merrill JE
    J Neuroimmunol; 1995 Mar; 57(1-2):179-91. PubMed ID: 7706435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Kliks S; Wright PF
    J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.